# **Journal of Visualized Experiments**

# Genetic engineering of axenic and non-axenic wild-type Dictyostelium discoideum cells based on the selection and growth on bacteria --Manuscript Draft--

| A C 1 T  | 1  |  |
|--|--|--|
| Article Type:  | Invited Methods Article - JoVE Produced Video  |  |
| Manuscript Number:   | JoVE58981R2  |  |
| Full Title:  | Genetic engineering of axenic and non-axenic wild-type Dictyostelium discoideum cells based on the selection and growth on bacteria                        |  |
| Keywords:  | Dictyostelium; transfection; knock-out; knock-in; extrachromosomal plasmids; act5; overexpression; Chemotaxis; motility; macropinocytosis; over expression |  |
| Corresponding Author:  | Peggy Paschke<br>MRC-LMB Cambridge<br>Cambridge, Cambridgeshire UNITED KINGDOM   |  |
| Corresponding Author's Institution:  | MRC-LMB Cambridge  |  |
| Corresponding Author E-Mail:   | ppaschke@mrc-lmb.cam.ac.uk   |  |
| Order of Authors:  | Peggy Paschke  |  |
|  | David A Knecht   |  |
|  | Thomas D Williams  |  |
|  | Peter A Thomason   |  |
|  | Robert H Insall  |  |
|  | Jonathan R Chubb   |  |
|  | Robert R Kay   |  |
|  | Douwe M Veltman  |  |
| Additional Information:  |  |  |
| Question   | Response   |  |
| Please indicate whether this article will be Standard Access or Open Access.   | Open Access (US\$4,200)  |  |
| Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations. | Cambridge, Cambridgeshire, United Kingdom  |  |

Dear Editor,

We should like to submit the paper entitled 'Rapid and efficient genetic engineering of both wild-type and axenic strains of *Dictyostelium discoideum*' by Peggy Paschke and co-workers for consideration by JOVE.

The paper meets a largely un-met need in the *Dictyostelium* field for molecular genetic techniques to manipulate wild-type and other non-axenic strains of *Dictyostelium* that can only grow on bacteria. This need exists because nearly all current molecular genetic work uses mutant axenic cells that have a high rate of macropinocytosis and can therefore grow in liquid medium, unlike wild-type cells which only grow well on bacteria.

Our methods are based on selection of transfected *Dictyostelium* cells on bacteria rather than liquid medium. We have developed a suite of new vectors for expression of genes and reporters, knock-outs and knock-ins, inducible expression, and including a 'safe haven' where integration gives stable and uniform expression between cells. The faster growth of cells on bacteria combined with optimised electroporation mean that these methods are much faster than standard, giving workable numbers of cells 2-3 days after a transformation.

Our methods are already being used in a number of laboratories, and we believe that this work will be of wide interest in the *Dictyostelium* community, offering as it does the ability to genetically manipulate virtually any strain at an unprecedented speed. The possibility to visualize the complete transfection process will be valuable to the community since most *Dictyostelium* researcher lack experience in growing *Dictyostelium* cells on bacterial lawn or suspension. A detailed video protocol will help to make the new transfection protocol more accessible for the whole community as well as newcomers in the field.

Yours sincerely,

Peggy Paschke

#### 1 TITLE:

2 Genetic Engineering of Dictyostelium discoideum Cells Based on Selection and Growth on

3 **Bacteria** 

#### 5 **AUTHORS & AFFILIATIONS:**

- Peggy Paschke<sup>1</sup>, David A Knecht<sup>2</sup>, Thomas D Williams<sup>1</sup>, Peter A Thomason<sup>3</sup>, Robert H Insall<sup>3</sup>, 6
- 7 Jonathan R Chubb<sup>4, 5</sup>, Robert R Kay<sup>1</sup>, Douwe M Veltman<sup>1</sup>

8 9

4

- <sup>1</sup>MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
- 10 <sup>2</sup>Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT, USA
- <sup>3</sup>Cancer Research UK Beatson Institute Glasgow, Glasgow, United Kingdom 11
- 12 <sup>4</sup>MRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom
- 13 <sup>5</sup>Department of Cell and Developmental Biology, University College London, London, United
- 14 Kingdom

15 16

## **Corresponding Author:**

17 Peggy Paschke (ppaschke@mrc-lmb.cam.ac.uk)

18 19

#### **Email Addresses of Co-authors:**

- 20 David A Knecht (david.knecht@uconn.edu)
- 21 Thomas D Williams (thomasw@mrc-lmb.cam.ac.uk)
- 22 Peter A Thomason (p.thomason@beatson.gla.ac.uk)
- 23 Robert H Insall (r.insall@beatson.gla.ac.uk)
- 24 Jonathan R Chubb (j.chubb@ucl.ac.uk)
- 25 Robert R Kay (rrk@mrc-lmb.cam.ac.uk)
- 26 Douwe M Veltman (douweveltman@gmail.com)

27

#### 28 **KEYWORDS:**

29 Dictyostelium, transfection, knock-out, knock-in, extrachromosomal plasmids, act5, 30

overexpression, chemotaxis, motility, macropinocytosis

31 32

33

34

35

#### **SUMMARY:**

Dictyostelium discoideum is a popular model organism to study complex cellular processes such as cell migration, endocytosis, and development. The utility of the organism is dependent on the

feasibility of genetic manipulation. Here, we present methods to transfect Dictyostelium

36 discoideum cells that overcome existing limitations of culturing cells in liquid media.

37 38

## **ABSTRACT:**

- 39 Dictyostelium discoideum is an intriguing model organism for the study of cell differentiation
- 40 processes during development, cell signaling, and other important cellular biology questions. The
- 41 technologies available to genetically manipulate Dictyostelium cells are well-developed.
- 42 Transfections can be performed using different selectable markers and marker re-cycling,
- 43 including homologous recombination and insertional mutagenesis. This is supported by a well-
- 44 annotated genome. However, these approaches are optimized for axenic cell lines growing in

liquid cultures and are difficult to apply to non-axenic wild-type cells, which feed only on bacteria. The mutations that are present in axenic strains disturb Ras signaling, causing excessive macropinocytosis required for feeding, and impair cell migration, which confounds the interpretation of signal transduction and chemotaxis experiments in those strains. Earlier attempts to genetically manipulate non-axenic cells have lacked efficiency and required complex experimental procedures. We have developed a simple transfection protocol that, for the first time, overcomes these limitations. Those series of large improvements to *Dictyostelium* molecular genetics allow wild-type cells to be manipulated as easily as standard laboratory strains. In addition to the advantages for studying uncorrupted signaling and motility processes, mutants that disrupt macropinocytosis-based growth can now be readily isolated. Furthermore, the entire transfection workflow is greatly accelerated, with recombinant cells that can be generated in days rather than weeks. Another advantage is that molecular genetics can further be performed with freshly isolated wild-type *Dictyostelium* samples from the environment. This can help to extend the scope of approaches used in these research areas.

#### **INTRODUCTION:**

The *Dictyostelium* genus are soil-living social amoeba that mainly feed on bacteria. Being placed in the phylum Amoebozoa, a large number of species have been isolated that can be grouped into four different clades<sup>1</sup>. The species *Dictyostelium discoideum* (*D. discoideum*) has become a popular model organism to study complex cellular processes such as cell migration and phagocytosis. To control and standardize experimental conditions, axenic cell lines have been developed that are able to grow in complex or defined liquid medium in the absence of bacteria<sup>2</sup>. Of particular importance are the Ax2, Ax3, and Ax4 strains, which were all generated in the 1970s and ultimately derived from a single wild isolate NC4<sup>3</sup>. Tools for genetic engineering were developed in these axenic strains, resulting in the first published knockout in 1987<sup>4,5</sup>. Protocols were further developed and optimized for use under axenic conditions<sup>6,7</sup>.

Adaptation of these protocols to wild-type *D. discoideum* strains that are not able to grow in liquid broth have been attempted by several laboratories. However, this has not become fully successful since the transfection protocols are complex and lack efficiency, in part due to the capacity of the bacteria to act as a sink for the selective reagents<sup>8,9</sup>. As a result, essentially all molecular data on *D. discoideum* comes from descendants of a single wild-type isolate. We wanted to overcome this limitation and develop a method to genetically modify *D. discoideum* cells independent of their ability to grow in liquid medium. The need for such a method can be explained by the observation that it was assumed in the past that the mutations allowing axenic growth were mainly neutral and did not impair cell physiology. This supposition is only partially correct. In general, there are two notable differences; first, between the different isolated axenic strains, and second, when these axenic strains are compared with non-axenic wild isolates<sup>8,9</sup>.

Perhaps the most critical factor is the key axenic gene, axeB, that was identified recently as RasGAP NF1. The major function of NF1 as a RasGAP is to restrain Ras activity<sup>3</sup>. The deletion of the enzyme in all axenic strains leads to excessive Ras activity manifested as the formation of large active Ras patches. These enlarged Ras patches lead to the accumulation of PIP3 in the plasma membrane. Those coincidental appearing patches of PIP3 and active Ras are a template

for the formation of a circular ruffle that eventually closes and leads to the formation of macropinosomes<sup>10</sup>. The consequence is an excessive increase in macropinocytic activity. Macropinocytosis is an actin-driven process. A competition for cytoskeletal components for the formation of either macropinosomes or pseudopods is the result. Its impact on cell behaviour is reflected in the almost complete prevention of chemotaxis of vegetative cells to folate<sup>11</sup>. The massively enlarged PIP3 patches are very persistent. Even in starved cells, the PIP3 patches remain and can be misinterpreted as pseudopods, which can cause problems interpreting studies on chemotaxis to cAMP.

In some cases, the NF1 mutation is experimentally useful. This leads us to a second motivation for developing a transfection method for bacterially grown *D. discoideum* cells, since the increase in macropinocytosis rate makes axenic cells valuable for investigating fundamental aspects of this process<sup>12</sup>. However, mutation in the genes required for macropinocytosis, such as Ras and PI3-kinases<sup>10</sup>, have almost abolished axenic growth, making it necessary to manipulate these cells through growth on bacteria. Another reason that renders bacteria-based transfections valuable is the increasing use of Dictyostelids to explore questions in the evolution of multi-cellularity<sup>13,14</sup>, kin recognition<sup>15,16</sup>, and altruistic cellular behaviour, which mainly depend on the use of freshly isolated wild-type isolates<sup>17</sup>. All mentioned research areas can be facilitated by efficient methods for genetic manipulation of wild isolates, which are non-axenic and do not grow in liquid broth.

Our protocols allow for overcoming of the described limitations. Taken together, the possibility of performing genetic manipulations with bacterial grown *D. discoideum* cells holds benefits for all *Dictyostelium* researchers, even if it is just the increased speed of the selection process due to faster growth of the amoeba (4 h doubling time) on bacteria compared to growth in axenic media (10 h doubling time).

## PROTOCOL:

## 1. Preparation of Cells and Materials

## 1.1. SorMC buffer preparation

1.1.1. Prepare 100 mL of 100x SorMC (Sorensen buffer including MgCl<sub>2</sub> and CaCl<sub>2</sub>) buffer by dissolving 20.36 g of KH<sub>2</sub>PO<sub>4</sub> (15 mM) and 5.47 g of Na<sub>2</sub>HPO<sub>4</sub>·7 H<sub>2</sub>O in 100 mL of ddH<sub>2</sub>O water. Stir the solution at room temperature (RT) and bring the volume to 100 mL with dH<sub>2</sub>O.

NOTE: The resulting buffer has a pH of 6 and does not need further adjusting.

1.1.2. Produce 1000 mL of 1x working solution in  $ddH_2O$ . Add 50  $\mu$ L each of  $MgCl_2$  and  $CaCl_2$  to achieve final concentrations of 50  $\mu$ M each. Filter sterilize the solution using a 0.22  $\mu$ m filter.

NOTE: Always add MgCl<sub>2</sub> and CaCl<sub>2</sub> to the 1x buffer to avoid precipitation of the salts in the 100x stock solution.

133 1.1.3. Alternatively, prepare  $KK_2$  buffer (2.2 g of  $KH_2PO_4$  and 0.7 g of  $K_2HPO_4$  for 1 L of buffer) supplemented with 50  $\mu$ M MgCl<sub>2</sub> and 50  $\mu$ M CaCl<sub>2</sub> (herein referred to as  $KK_2MC$ ). Use this buffer throughout instead of SorMC.

136137

## 1.2. Preparation of bacteria as food source for *D. discoideum*

138

139 1.2.1. Use a single colony of *K. aerogenes* and inoculate 1 L of LB-medium (lysogeny broth). Use a 2 L flask. Let bacteria grow overnight at 37 °C with shaking at 220 rpm.

141142

NOTE: If large amounts of bacteria are required, use richer media like 2xTY (yeast extract tryptone medium) or SOB (super optimal broth) instead of LB. In case the use of *K. aerogenes* bacteria is not permitted due to safety restrictions, BL21 *E. coli* can be used instead.

144145

143

146 1.2.2. Harvest the cells the next day by spinning them down in two 500 mL centrifuge tubes at 26600 x g for 20 min. Wash bacteria once with 500 mL of SorMC buffer.

148

149 1.2.3. Resuspend the pellet in 20 mL of SorMC. Check the OD<sub>600</sub> (optical density at 600 nm) using a photometer. Dilute with the same buffer to an OD<sub>600</sub> of around 100.

151

NOTE: *K. aerogenes* bacteria are difficult to pellet, so a relatively high speed for spinning down the bacteria is necessary to avoid loss of food bacteria. The resulting bacterial stock solution can be stored for up to 4 months in the fridge at 4 °C and maintain its utility as food source for *D. discoideum*. 1 L of overnight *K. aerogenes* suspension grown in LB medium usually yields 20 mL of an OD<sub>600</sub> of around 100.

157

158 CAUTION: To ensure that the prepared bacteria are a monoculture of *K. aerogenes*, perform all steps under a hood.

160 161

1.3. Preparation of H40 electroporation buffer

162163

164

1.3.1. Prepare 100 mL of buffer solution, dissolve 0.952 g of HEPES in ddH<sub>2</sub>O water, and add 100  $\mu$ L of MgCl<sub>2</sub> from a 1 M stock solution. Adjust to pH 7 using KOH for titration. Sterilize the buffer using a 0.22  $\mu$ m filter or autoclave. Use acid-free HEPES and not the sodium salt.

165 166

1.4. Perform plasmid preparation following the manufacturer's protocol and using the kits summarized in the **Table of Materials**. Use the plasmids summarized in **Table 1**.

169

NOTE: The quality of DNA used for transfection is crucial. The selection of *D. discoideum* transfectants growing on bacteria has specific requirements for the promoters driving the selection and expression cassette (see discussion).

173

174 [Insert Table 1 here]

175 176

1.5. Setting up Dictyostelium cells for transfection

178 1.5.1. Grow *K. aerogenes* to confluence in SM medium (nutrient-rich medium) overnight at RT.
179 Cultures can be stored for up to 2 weeks at 4 °C.

180

1.5.2. Add about 400 μL of this bacterial suspension onto a SM agar plate (peptone 10 g/L; yeast extract 1 g/L; glucose 10 g/L; KH<sub>2</sub>PO<sub>4</sub> 1.9 g/L; K<sub>2</sub>HPO<sub>4</sub> x 3 H<sub>2</sub>O, 1.3 g/L; MgSO<sub>4</sub> anhydrous 0.49 g/L;
 1.7% agar) and spread evenly. Take a sterile loop and inoculate with *Dictyostelium* cells. Spread the cells at one edge of the plate.

185

186 1.5.3. Incubate the plate at 22 °C for 2 days to ensure sufficiently large growth zones for transfection.

188

NOTE: For *Dictyostelium* strains that do not make large growth zones (*e.g.,* Ax3, DH1, or JH10), or for inexperienced experimenters, use clearing plates instead. For this, follow the instructions in steps 1.5.4 to 1.5.6.

192

1.5.4. Take a sterile loop and inoculate with *Dictyostelium* cells (approximately 2–4 x  $10^5$  cells).

Transfer the cells to 800  $\mu$ L of a dense *K. aerogenes* suspension in SM. Mix cells by pipetting up and down.

196

197 1.5.5. Transfer 400  $\mu$ L, 200  $\mu$ L, 100  $\mu$ L, and 50  $\mu$ L on fresh SM agar plates. Add to every plate 400  $\mu$ L of additional SM *K. aerogenes* suspension, spread evenly, and dry.

199200

1.5.6. Incubate the plates at 22 °C for about 2 days until the plates become translucent.

201202

NOTE: Due to their faster growth rate, the bacteria initially produce a confluent lawn, and the amoebae subsequently "clear" the plate of the bacteria. The time required for this process can differ depending on the strain background and ability of mutant cells to grow on bacteria.

204205206

203

## 2. Transfection of *Dictyostelium* Cells Based on Bacterial Selection

207208

## [Insert Figure 1 here]

209210

211

212

2.1. To prepare plates with *K. aerogenes* suspension, add 10 mL of SorMC buffer containing *K. aerogenes* bacteria to a density of  $OD_{600} = 2$  (add 200  $\mu$ L of the prepared  $OD_{600} = 100$  *K. aerogenes* stock solution for the desired bacteria concentration) into a 10 cm tissue culture treated petri dish.

213214215

216

217

NOTE: This plate is later needed to cultivate the transfected D. discoideum cells. Alternatively, a 6-well tissue-culture plate can be used. In the case of transfection of the extrachromosomal plasmids, the 6-well tissue-culture plate is more resource-efficient. Use 2 mL of K. aerogenes SorMC (OD<sub>600</sub> = 2) suspension per well.

218219220

## 2.2. Preparation of Dictyostelium cells

221

2.2.1. Using a 10 μL disposable inoculation loop, scrape cells from the growth zones
 (approximately 3 cm) of the culture plate (edge of the cleared area) or clearing plate. Transfer
 cells into a 1.5 mL tube containing 1 mL of ice-cold H40 buffer.

225 226

227

NOTE: The timing of harvesting cells from clearing plates is crucial. Harvesting too early yields too little an amount of cells, while harvesting to late increases the risk of yielding partially developed cells

228229

2.2.2. Wash the cells by spinning down for 2 min at 1000 x g or flash-spinning for 2 s at 10,000 x g. Discard the supernatant and resuspend cells in H40 buffer to a final density of 2–4 x 10<sup>7</sup> cells/mL. Keep the cells cold during the whole transfection procedure. Use an ice-water slurry to ensure direct contact of the tubes and ice.

234

2.3. Electroporation

235236

237 2.3.1. Add 100 μL of cells to a tube with 1–2 μg of DNA. Mix carefully by pipetting up and down.

238

239 2.3.2. Transfer the cell/DNA mixture into a pre-chilled electroporation cuvette (2 mm gap).

240

241 2.3.3. Pulse the cells using the following square-wave settings: 350 V, 8 ms, 2 pulses, and 1 s pulse interval.

243 244

NOTE: Do not add more than 2  $\mu$ g of DNA. Higher amounts are toxic to cells and decrease transfection efficiency. The total added DNA volume should not exceed 5  $\mu$ L.

245246

2.3.4. Transfer cells immediately to the earlier prepared 10 cm Petri dish with *K. aerogenes*248 SorMC and allow the cells to recover for 5 h.

249250

251

NOTE: Check the cells in the Petri dish under an inverted microscope. Cells will appear round directly after electroporation but will return to their amoeboid shape after about 30 min, when they have had enough time to attach properly to the surface.

252253254

255

256

2.4. Selection of transfectants: depending on whether transfection is aimed to generate a knock-out, knock-in, or *act5* knock-in, or to express a fluorescent reporter protein from an extrachromosomal plasmid, carry out the selection process through one of the following described methods.

257258

NOTE: Unlike axenically grown cells, bacterially grown cells are highly resistant to blasticidin.
Selection, therefore, is always carried out using G418 or hygromycin (see discussion).

261

262 **2.4.1** Knock-outs, knock-ins, and act5 knock-ins

263

2.4.1.1. Detach the cells carefully from the Petri dish by repeatedly forcing the liquid from a

| 2/1<br>272 | derogenes stock solution.  |
|------------|--|
| 273        | 2.4.1.4. Medium dilution: mix 900 μL of cell suspension with 28.5 mL of SorMC and 600 μL of K.   |
| 274        | aerogenes stock solution.  |
| 275        |  |
| 276        | 2.4.1.5. High dilution: mix 90 μL of cell suspension with 29.3 mL of SorMC and 600 μL of K.      |
| 277        | aerogenes stock solution.  |
| 278        |  |
| 279        | 2.4.1.6. Add 30 μL of selectable marker (100x stock solution).                                   |
| 280        |  |
| 281        | 2.4.1.7. Distribute the prepared dilutions into 96-well flat-bottom tissue culture plates by     |
| 282<br>283 | pipetting 150 μL of cell suspension into each well.  |
| 284        | NOTE: This procedure aims to screen single clones rather than populations. The selection takes   |
| 285        | about 5–7 days, depending on the construct used.   |
| 286        | about 5 7 days, depending on the constituer about  |
| 287        | 2.4.2. Chromosomal plasmids  |
| 288        |  |
| 289        | 2.4.2.1 Add the selectable marker directly to the 10 mL dish (see Figure 1).                     |
| 290        |  |
| 291        | NOTE: There is no need to set up dilutions, since there is no desire for clonal populations. The |
| 292        | selection process for extrachromosomal plasmids is faster due to high copy numbers present in    |
| 293        | D. discoideum cells. Transfectants can be expected after 32 h to 2 days.                         |
| 294<br>295 | CAUTION: The antibiotics used as selectable marker are toxic. Wear gloves                        |
| 295<br>296 | CAUTION: The antibiotics used as selectable marker are toxic. Wear gloves.                       |
| 297        | 2.5. Screen the obtained clones for positive tranfectants. For knock-out or knock-in attempts,   |
| 298        | follow the instructions in step 2.9.1. Check transfection success for extrachromosomal plasmids  |
| 299        | using the instructions in step 2.9.2.  |
| 300        |  |
| 301        | 2.5.1. For knock-outs, knock-ins, and act5 knock-ins, perform the initial screen via PCR to      |
| 302        | confirm integration of the construct into the correct genomic locus.                             |
| 303        |  |
| 304        | NOTE: To maximize the likelihood of clonal populations, use the highest dilution possible that   |
| 305        | yields transfectants after selection. Aim for plates that are a maximum one-third of wells       |
| 306        | occupied.  |
| 307        |  |

2.5.1.1. To expand clonal populations, transfer clones that have grown up after selection from

revised November 2017

2.4.1.2. Set up three dilutions in the SorMC K. aerogenes suspension (OD<sub>600</sub> = 2) and add the

2.4.1.3. Low dilution: mix 9 mL of cell suspension with 20.4 mL of SorMC and 600 μL of K.

selective agent according to the resistance used (see Figure 1).

pipette onto the surface.

265266

267

268269

270

308

Page 6 of 6

the 96-well tissue-culture plate into a 12-well tissue-culture plate to grow enough cells for the isolation of genomic DNA. Supply each well with 1 mL of SorMC K. aerogenes (OD<sub>600</sub> = 2) and fresh selectable marker.

311312313

309

310

NOTE: 1 day is usually sufficient to obtain a confluent well suitable for DNA isolation.

314

2.5.1.2. To perform mini genomic DNA isolation, harvest the cells of a confluent well and isolate
 genomic DNA using a mini DNA extraction kit following the manufacturer's instructions.

317

2.5.1.3. Use the isolated genomic DNA together with suitable primers and Taq-polymerase (see
 Table of Materials) to PCR screen for positive integrands.

320 321

322

NOTE: After confirmation of positive integration into the correct genomic locus, a Southern blot analysis should be performed. This ensures greater confidence that additional insertion events in unspecific genomic regions have not occurred.

323324

[Insert Table 2 here]

325326327

2.5.2. For fluorescent reporter proteins, visually identify positive fluorescent cells and check with a fluorescence microscope. Alternatively, perform a western blot with suitable antibodies for biochemical identification.

329 330 331

328

**REPRESENTATIVE RESULTS:** 

332333

334

335

336

337

338

339

340

341

342

343

344 345

346

347

Extrachromosomal plasmids are used for reporter studies, which aim to identify the localization of certain proteins inside a cell or changes in cellular structure of mutant cells. For many approaches, such as monitoring of the cell cycle, it is crucial to express two reporters at the same time. This is now possible using our dual reporter extrachromosomal plasmid system (Table 1). On day 1, cells were transfected before adding the selectable marker G418 after 5 h (Figure 1). In the example, NC4, DdB, Ax2, and the independently derived wild isolates V12M2 and WS2162 (Supplementary Table 1) were transfected with the plasmid pPI289, which encodes for GFPtubulinA, a marker for microtubules and mCherry-PCNA, a protein that is used for monitoring the cell cycle (Figure 2A). After 32 h, the cells were observed under the microscope. The majority of cells expressed both fluorescent-labeled fusion proteins, consistent with previous reports that expression of two reporters from the same plasmid shows similar expression levels, which is nearly impossible when using two different plasmids 18,19. A representative cell for each cell line (NC4, DdB, Ax2, V12M2, and WS2162) expressing the desired dual reporter is shown in Figure 2B. The transfection efficiencies are summarized in Figure 2C. NC4-derived cell lines show the best transfection efficiencies. However, for cell lines V12M2 and WS2162, a considerably high number of transfectants was obtained.

348349

[Insert Figure 2]

350 351 352

Integration of a targeting vector into a specified genomic locus is more challenging and requires

more careful analysis of the generated cell line. In **Figure 3**, an *act5*-mCherry KI in NC4 is attempted. First, the plasmid must be linearized to increase the frequency of recombination events following transfection. For this, the plasmid pDM1514 is cut with *Ngo*MIV. Two bands are obtained after running the digest on an agarose gel. The 4127 bp band contains the desired construct (**Figure 3**). For transfection, the digested DNA must be extracted from the gel and purified using a gel extraction kit following the manufacturer's instructions.

## [Insert Figure 3]

The purified DNA was used for transfection of NC4 cells. After 5-6 days of selection, clones were obtained. Representative transfection efficiencies and the amount of positive identified clones for several *act5* knock-in attempts are summarized in **Table 3**. Two clones of the NC4 transfection were randomly chosen and analyzed by PCR (**Figure 4A**), and both showed the predicted band patterns expected of a knock-in and were further validated with Southern blot analysis to ensure a single integration event of the construct into the genome<sup>20</sup>. The blot shows a clear single integration in the desired *act5* locus (**Figure 4B**). The generated *NC4::act5-mCherry* cell line can now be used in experiments.

#### [Insert Figure 4]

## [Insert Table 3]

The *act*5 locus offers relatively homogenous expression of the integrated reporter<sup>21</sup>. The generated *NC4::act5-mCherry* cells allow mix experiments to be performed with other *act5* knock-ins using a different fluorescent protein such as GFP. To emphasize the great advantage of this system, mixing experiments with *Ax2::act5-GFP* are shown. Due to the inability to transfect non-axenic wild-type cells, this type of approach could not be performed before. Mix experiments are an important tool to analyze cell behavior, because they allow a direct comparison between different cell lines experiencing identical experimental conditions. NC4 cells grow faster on bacterial lawns than Ax2 cells (**Figure 5A**). This may be due to a higher capacity to phagocytose bacteria or improved ability to move and show chemotaxis towards a food source. Using an under-agar folate chemotaxis assay, direct comparison of a population of *NC4::act5-mCherry* and *Ax2::act5-GFP* was performed, showing that *NC4::act5-mCherry* are much more efficient in folate sensing. After 4 h, more *NC4::act5-mCherry* cells were able to crawl under the agarose than *Ax2::act5-GFP* cells (**Figure 5B**). Analyzing standard metrics of chemotaxis for the cells migrating under the agarose revealed that *NC4::act5-mCherry* cells were faster and showed stronger chemotactic response than *Ax2::act5-GFP* cells (**Figure 5C-E**).

## [Insert Figure 5]

The *act5* knock-in cell lines can also be used for flow cytometry. As with growth on bacteria, there are major differences in development between axenic strains and non-axenic wild-types. After development, the fruiting bodies of NC4 cells are approximately twice as big as those derived from Ax2 cells. If cells are mixed, an intermediate sized fruiting body is obtained. To analyze the

contribution of the both cell lines more quantitatively, flow cytometry was used. These analyses showed clearly that the intermediate-sized fruiting bodies are due to different levels of contribution from both cell lines. While *NC4::act5-mCherry* cells made up about 75% of the measured spores, *Ax2::act5-GFP* contributed only 25%, revealing a potential fitness advantage for non-axenic strains (**Figure 6**). Since the analysis does not monitor the stalk cell population, there are two possibilities to explain the imbalance in development between Ax2 and NC4. One possibility is that Ax2 cells contribute mainly to the stalk cell population, rather than entering the spore cell population. Alternatively, more NC4 cells may enter the developmental cycle, with Ax2 relatively delayed, and they are consequently unable to contribute to the assembly of a fruiting body. The possibility to transfect non-axenic wild-type cells further develops other approaches and greatly simplifies experimental procedures.

[Insert Figure 6]

## **FIGURES AND TABLE LEGENDS:**

Figure 1: Workflow for the transfection of bacteria-grown *Dictyostelium* cells. The steps for transfection are listed as follows. Grow *D. discoideum cells* on a SM plate seeded with *K. aerogenes* bacteria (red). Harvest cells only from the feeding front (green), avoiding cells that are already developing (dark green). Wash the cells in H40. Resuspend cells to a final density of 2–4 x  $10^7$  cells/mL. Mix the cell suspension with 1-2 µg of DNA. Transfer the mixture to an electroporation cuvette and pulse cells. Transfer the cells directly after electroporation to a dish with SorMC and bacteria. Allow the cells to recover for 5 h before adding the selectable marker. For extrachromosomal plasmids, add the selection directly to the dish. Transfectants are usually visible after ~2 days. For linearized constructs that aim for single integration into the genome, set up three dilutions as indicated and add the selection. Bacteria are taken from the OD<sub>600</sub> = 100 stock solution. Mix the tubes well and transfer the cells into 96-well flat-bottom tissue culture plates. Use two plates per dilution. Pipette 150 µL of cell suspension into every well. It takes about 5 days until tight colonies are visible. The red wells show an example of the usual amount of successfully transformed cells obtained (upper panel modified from previous publication<sup>22</sup>).

**Figure 2: Expression of an extrachromosomal plasmid.** (A) Extrachromosomal plasmids are directly transfected in circular form. As an example, the dual reporter pPI289 is shown. The *Ngo*MIV sites indicate insertion of the second reporter into the extrachromosomal expression plasmid. (B) Z-projection of a representative cell expressing GFP-TubulinA (cytoplasmic) and mCherry-PCNA (largely nuclear) for five different wild-type cell lines used (NC4, DdB, Ax2, V12M2, WS2162). (C) The transfection efficiencies for the five cell lines pictured in (B) were calculated. Shown is the mean of two experiments. Error bars indicate ± SD.

**Figure 3: Preparation of** *act5* **knock-in and DNA for transfection.** An example of the use of an *act5* knock-in the plasmid pDM1514 is shown. The steps for preparation are listed as follows. (**A**) Before electroporation, linearize the plasmid using the indicated *Ngo*MIV sites. (**B, C**) Run the cut plasmid on an agarose gel until the two expected bands are properly separated. Cut out the 4127 bp band containing the recombination arms, mCherry, and the resistance-cassette, and gel

extract the DNA. The DNA is now ready for transfection.

Figure 4: Validation of act5-mCherry KIs in NC4. (A) Scheme and control PCRs for the validation of positive integrations into act5 locus. The indicated primers were used to analyze two independent clones and the parent. Both clones show the expected bands for the resistance-cassette and downstream (P1) or upstream primer (P2), which are not present in the parental strain. The primer combination (P1/P2) confirms the correct integration of mCherry and resistance cassette into the act5 locus. The wild-type NC4 shows the expected 2800 bp band, while both KI clones lack this band and instead display a PCR product about 1400 base pairs larger. (B) Scheme for the used restriction digest and Southern blot. Both knock-in clones show the smaller 3400 bp band, which is the result of integration of the construct into the act5 locus, specifically the additional Bcl1 site in the hygromycin resistance cassette. The wild-type control shows the expected 5.8 kb resulting from the two downstream located Bcl1 sites. The blot was cropped and spliced for clarity.

Figure 5: Using act5 KIs for image-based chemotaxis mix experiments. (A) NC4::act5-mCherry and Ax2::act5-GFP expressing the indicated fluorescent protein from the act5 locus were analyzed for the ability to grow on a bacterial lawn. After 4 days, the plaque diameter arisen from solitary plated Dictyostelium cells were measured. Non-axenic act5::NC4 cells make significantly bigger plaques than axenic Ax2::act5-GFP cells (mean  $\pm$  SD, \*\*\*p < 0.0001, n = 3, scale bar 5 mm). (B) For use of the under-agarose folate chemotaxis assay<sup>22</sup> to directly compare the chemotactic abilities of the NC4::act5-mCherry and Ax2::act5-GFP used in (A), bacteria- grown amoebae of both strains were mixed in a 50:50 ratio. Cells were allowed to crawl under the agarose. After 4 h, cells that were migrating up the folate gradient were imaged using a confocal microscope. The number of NC4::act5-mCherry and Ax2::act5-GFP cells was then determined. NC4::act5-mCherry cells were more efficient in sensing folate. About 10-fold more NC4::act5-mCherry cells were found compared to Ax2::act5-GFP cells (mean  $\pm$  SD, \*\*\*p < 0.0001, n = 6, scale bar 100  $\mu$ m). (C, D) The cells were filmed for 60 min, and their speed and chemotactic index were calculated. After pre-selection of the most chemotactically responsive cells (only those that migrated under the agarose), Ax2::act5-GFP cells showed lower values for both cell speed and chemotaxis. Fifty cells per cell line were analyzed. (median  $\pm$  SD, \*p < 0.01, n = 3). (E) The tracks of NC4::act5-mCherry and Ax2::act5-GFP act5 knock-ins are plotted over 60 min, showing the more directed movement towards the chemoattractent source of the NC4::act5-mCherry cells (median ± SD, \*\*\*p < 0.0001, n = 6).

**Figure 6:** Act5 KIs allow analysis of mix experiments using flow cytometry. (A) NC4::act5-mCherry and Ax2::act5-GFP were developed separately or in a 50:50 mixture on non-nutrient agar plates. NC4::act5-mCherry cells form larger fruiting bodies than Ax2::act5-GFP. The mix instead shows an intermediate size (scale bar 5 mm). Confocal fluorescence light microscopy suggests a higher amount of NC4::act5-mCherry spores in the spore heads derived from mixes. (B) To quantify this observation, the amounts of spores in harvested spore heads from the mixing experiment in (A) were analyzed by flow cytometry. About 75% of the spores originated from NC4::act5-mCherry cells, with only 25% from Ax2::act5-GFP cells. (C) Representative distribution of spores from both cell lines shown in a flow cytometry scatter. About 0.05% show positive

mCherry and GFP signals, suggesting that parasexual fusion processes have occurred or that spores are sticking to each other.

Table 1: Plasmid list for non-axenic transfections.

Table 2: PCR program and sample composition for the amplification of *D. discoideum* genomic DNA.

Table 3: Transfection efficiencies and the amount of obtained positive transfectants for the generation of *act5* KIs in different strain backgrounds<sup>22</sup>.

Supplementary Table 1: Different strains of *Dictyostelium* studied.

**DISCUSSION:** 

The use of non-axenic, wild-type *Dictyostelium* cells has been very limited so far in molecular research. Available methods for genetic engineering of these strains have lacked reliability and efficiency<sup>23</sup>, preventing their general adoption. The generated materials and protocols presented here can be used for any *D. discoideum* strain independent of its ability to grow in liquid medium. It should be mentioned that this protocol is optimized for NC4-derived cell lines. Transfection efficiencies for freshly isolated strains from the wild differ from NC4, as we have observed before and are shown here for V12M2 and WS2162<sup>8,9</sup>. The electroporation conditions seem in particular to have a considerable influence on transfection efficiencies and may require further optimization for some strains. In general, a sufficient amount of transfectants have been observed in all strains tested so far, showing that these methods are workable. The number of positive transfectants obtained using NC4-derived strains is higher compared to other non-axenic wild-type strains, but in all cases, sufficient numbers of transfectants are obtained to allow for further experiments. This, plus the simplicity of our protocol, is the major improvement compared to earlier attempts<sup>8,9</sup>.

These new non-axenic protocols cover all standard genetic procedures and add further advantages, since transfections can be performed rapidly and efficiently in parallel. Positive clones can be obtained in days rather than weeks, since growth on bacteria halves the division time. The newly established plasmids also work under axenic conditions and can be routinely used under both growth conditions, which is another advancement of this methology<sup>22</sup>. As introduced in the protocol, the plasmid used for selection on bacteria have special requirements that are crucial for the success of the transfection. In particular, the promoters driving the expression and resistance cassettes are important for successful transfection. The often used *act6* (actin 6) promoter<sup>24</sup> for driving the resistance or expression cassettes lacks efficiency when cells are grown on bacteria. In our plasmid system, the highly active *act15* (actin 15) promoter drives all expression cassettes, while the resistance cassettes are under the control of a *coA* (coactosin A) promoter, both of which are active under axenic conditions and in cells grown on bacteria. Requirements for the expression of reporter constructs as well as knock-in and knock-out constructs make it necessary to use our plasmid repertoire, but unfortunately limits the use

of vectors already created that use the inefficient *act6* promoter.

529530531

532

533

534

535

536537

538

539

540

541

542

543

544

545

546

547

548

Promoter efficiencies are especially critical for transfections that depend on a single integration event into the correct genomic locus. Due to our improvement of promoters driving the resistance gene expression, enough resistance protein is produced from single locus integrations. A major concern was the favoring of multiple integrations into the genome when using hygromycin or G418 as described. No favoring of multiple integrations has been observed so far, as reported previously for G418 selections using older promoter systems<sup>25</sup>. This means that both hygromycin and G418 are suitable selectable markers for the generation of clean knock-outs and knock-ins. Unfortunately, the selectable marker blasticidin does not work under non-axenic conditions. This is a major disadvantage of our method, since the blasticidin resistance cassette is routinely used to generate knock-out constructs in D. discoideum. Constructs that were already generated with blasticidin resistance cassettes will need to be rederived using one of the workable selectable markers. Another possibility to overcome this limitation is to combine the recently established axenic D. discoideum CRISPR technology with this transfection protocol<sup>26</sup>. The generation of suitable, single guide RNAs (sgRNAs) is simpler and faster than the reconstruction of complete knock-out constructs. For future directions, the possibility of generating multiple knock-outs using CRISPR/Cas9 combined with this transfection protocol is appealing and may pave the way for many researchers in the Dictyostelium community. However, the workability of the established transient expression system used for CRISPR/Cas9 in axenic grown cells should be carefully examined.

549550551

552

553554

555

556

557

558

559

560

561562

563

The *act5* knock-in system presented offers a reliable and safe integration system for the generation of stable cell lines in *D. discoideum*, with the advantage of similar sites established in other organisms<sup>22</sup>. It also depends on a single integration event in the genome and offers many possibilities for different research directions. The *act5* promoter is strongly active and guarantees almost homogenous expression<sup>27</sup> independent of the cultivation conditions. Fluorescent reporter proteins can easily be integrated into this safe haven locus using the engineered targeting plasmids. This can be useful, for example, for cell-tracking purposes, as shown here in a mix experiment. The cells show minimal cell-to-cell expression variability, which can assist in automated cell tracking. Importantly, the insertion of a desired sequence into the *act5* locus appears phenotypically neutral<sup>28,29</sup>. As the expression does not depend on a selectable marker to maintain protein expression, as seen in random integrants or extrachromosomal vector-bearing cell lines, the *act5* system can be useful for rescue experiments, as well. Since the cell lines are homogenous, all cells can be analyzed. This is not possible using an extrachromosomal plasmid for expression, in which there is considerable heterogeneity in expression.

564565566

567

568

569

570571

572

In addition to these general improvements for all strains, the ability to use non-axenic wild-type cells for molecular research allows an assessment of the effects of accumulated mutations in current laboratory strains. Multiple genetic rearrangements has been found since the adoption of the Ax2 strain in 1970, as shown by previously published microarray analyses<sup>26</sup>. Synthetic phenotypes are observed because of the presence of these mutations. For example, a reported *phg*2 mutant shows decreased adhesion in one laboratory strain background and increased adhesion in another<sup>3</sup>. Such conflicting data can now be resolved by repeating the experiment in

the common ancestor strain (in this case, DdB). The strength of this approach has been recently shown for the small GTPase RasS<sup>30,31</sup>.

575 576

577

578

581

582

583

584

585

The ability to perform genetic experiments in any *D. discoideum* strain expands the potential of new research directions that depend on the use of wild isolates, notably those involving social evolution, kin recognition, and the sexual cycle<sup>22</sup>.

579 580

#### **ACKNOWLEDGMENTS:**

The authors thank the Kay lab for input to this method and the LMB microscopy and flow cytometry facilities for excellent scientific and technical support. This work was funded by Medical Research Council grant MC\_U105115237 to R. R. Kay, BBSRC (Biotechnology and Biological Sciences Research Council) grant BB/K009699/1 to R. R. Kay, Cancer Research UK grant A15672 to R. H. Insall, Wellcome Trust Senior Fellowship 202867/Z/16/Z to Jonathan R Chubb, and MRC funding (MC\_U12266B) to the MRC LMCB University Unit at UCL.

586 587 588

#### **DISCLOSURES:**

The authors have no conflicts of interest to disclose.

589 590 591

#### **REFERENCES:**

592

- 593 1 Schaap, P. Evolutionary crossroads in developmental biology: Dictyostelium discoideum. 594 Development. **138** (3), 387-396 (2011).
- 595 2 Sussman, R., Sussman, M. Cultivation of Dictyostelium discoideum in axenic culture. 596 *Biochemical and Biophysical Research Communications.* **29,** 53-55 (1967).
- Bloomfield, G., Tanaka, Y., Skelton, J., Ivens, A., Kay, R. R. Widespread duplications in the genomes of laboratory stocks of Dictyostelium discoideum. *Genome Biology.* **9** (4), R75 (2008).
- Witke, W., Nellen, W., Noegel, A. Homologous recombination in the Dictyostelium alphaactinin gene leads to an altered mRNA and lack of the protein. *The EMBO Journal.* **6,** 4143-4148 (1987).
- De Lozanne, A., Spudich, J. A. Disruption of the Dictyostelium myosin heavy chain gene by homologous recombination. *Science.* **236**, 1086-1091 (1987).
- 605 6 Howard, P. K., Ahern, K. G., Firtel, R. A. Establishment of a transient expression system for Dictyostelium discoideum. *Nucleic Acids Research.* **16**, 2613-2623 (1988).
- Knecht, D., Pang, K. M. Electroporation of Dictyostelium discoideum. *Methods in Molecular Biology.* **47,** 321-330 (1995).
- Wetterauer, B. *et al.* Wild-type strains of Dictyostelium discoideum can be transformed using a novel selection cassette driven by the promoter of the ribosomal V18 gene. *Plasmid.* **36,** 169-181 (1996).
- 612 9 Lloyd, M. M., Ceccarelli, A., Williams, J. G. Establishment of conditions for the 613 transformation of nonaxenic Dictyostelium strains. *Developmental Genetics*. **11**, 391-395 614 (1990).
- Bloomfield, G. *et al.* Neurofibromin controls macropinocytosis and phagocytosis in Dictyostelium. *eLife.* **4**, (2015).

- Veltman, D. M. *et al.* A plasma membrane template for macropinocytic cups. *eLife.* **5**, (2016).
- Veltman, D. M., Lemieux, M. G., Knecht, D. A., Insall, R. H. PIP(3)-dependent macropinocytosis is incompatible with chemotaxis. *The Journal of Cell Biology.* **204** (4), 497-505 (2014).
- Hoeller, O., Kay, R. R. Chemotaxis in the absence of PIP3 gradients. *Current Biology.* **17,** 813-817 (2007).
- 624 14 Chubb, J. R., Wilkins, A., Thomas, G. M., Insall, R. H. The Dictyostelium RasS protein is 625 required for macropinocytosis, phagocytosis and the control of cell movement. *Journal of* 626 *Cell Science.* **113,** 709-719 (2000).
- Schaap, P. *et al.* Molecular phylogeny and evolution of morphology in the social amoebas. *Science.* **314**, 661-663 (2006).
- Du, Q., Kawabe, Y., Schilde, C., Chen, Z. H., Schaap, P. The Evolution of Aggregative Multicellularity and Cell-Cell Communication in the Dictyostelia. *Journal of Molecular* Biology. **427** (23), 3722-3733 (2015).
- Hirose, S., Benabentos, R., Ho, H. I., Kuspa, A., Shaulsky, G. Self-recognition in social amoebae is mediated by allelic pairs of tiger genes. *Science.* **333** (6041), 467-470 (2011).
- Strassmann, J. E., Queller, D. C. Evolution of cooperation and control of cheating in a social microbe. *Proceedings of the National Academy of Sciences of the United States of* America. **108** (2), 10855-10862 (2011).
- Wolf, J. B. *et al.* Fitness Trade-offs Result in the Illusion of Social Success. *Current Biology.* **25** (8), 1086-1090 (2015).
- Veltman, D. M., Akar, G., Bosgraaf, L., Van Haastert, P. J. A new set of small, extrachromosomal expression vectors for Dictyostelium discoideum. *Plasmid.* **61** (2), 110-118 (2009).
- Southern, E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. *Journal of Molecular Biology.* **98** (3), 503-517 (1975).
- Paschke, P. *et al.* Rapid and efficient genetic engineering of both wild type and axenic strains of Dictyostelium discoideum. *PLoS One.* **13** (5), e0196809 (2018).
- Woznica, D., Knecht, D. A. Under-agarose chemotaxis of Dictyostelium discoideum. *Methods in Molecular Biology.* **346,** 311-325 (2006).
- Dubin, M., Nellen, W. A versatile set of tagged expression vectors to monitor protein localisation and function in Dictyostelium. *Gene.* **465** (1-2), 1-8 (2010).
- de Hostos, E. L. *et al.* Dictyostelium mutants lacking the cytoskeletal protein coronin are defective in cytokinesis and cell motility. *Journal of Cell Biology.* **120**, 163-173 (1993).
- Sekine, R., Kawata, T., Muramoto, T. CRISPR/Cas9 mediated targeting of multiple genes in Dictyostelium. *Scientific Reports.* **8** (1), 8471 (2018).
- Sadelain, M., Papapetrou, E. P., Bushman, F. D. Safe harbours for the integration of new DNA in the human genome. *Nature Reviews Cancer.* **12** (1), 51-58 (2011).
- Rosengarten, R. D. *et al.* Leaps and lulls in the developmental transcriptome of Dictyostelium discoideum. *BMC Genomics.* **16**, 294 (2015).
- Tunnacliffe, E., Corrigan, A. M., Chubb, J. R. Promoter-mediated diversification of transcriptional bursting dynamics following gene duplication. *Proc Natl Acad Sci USA*. **115** (33), 8364-8369 (2018).

| 661 | 30 | Gebbie, L. et al. Phg2, a kinase involved in adhesion and focal site modeling in                   |
|-----|----|--|
| 662 |    | Dictyostelium. Molecular Biology of the Cell. 15, 3915-3925 (2004).                                |
| 663 | 31 | Jeon, T. J., Lee, D. J., Merlot, S., Weeks, G., Firtel, R. A. Rap1 controls cell adhesion and cell |
| 664 |    | motility through the regulation of myosin II. Journal of Cell Biology. 176, 1021-1033              |
| 665 |    | (2007).  |
| 666 |    |  |

Wash once in H40 buffer Add 1 μg DNA transfer to dish with SorMC + bacteria (10 mL)















scrape cells from the growth zone

electroporate

cells recovery for 5 h







extrachromosomal plasmids

Selection marker:

or Hygromycin\*\*

t = 32 h

20 μL G418\*

## Knock-outs, Knock-ins and act5-Knock-ins




high











90 μL

900 μL

9 mL

Bacteria:

600 μL

600 μL

600 μL

Selection marker (G418\*or Hygromycin\*\*):

 $30 \, \mu L$ 

30 μL

30 μL

SorMC buffer:

29.3 mL

28.5 mL


20.4 mL











150 μL per well, 2x 96 well plates per dilution















t = 120 h


\* stock solution: 10 μg/mL


\*\* stock solution: 100 μg/mL





C














| plasmid name | resistance/selection in bacteria |  |  |
|--------------|----------------------------------|--|--|
|              | extrachromoso                    |  |  |
| pDM1203      | Ampicilin                        |  |  |
| pDM1207      | Ampicilin                        |  |  |
| pDM1208      | Ampicilin                        |  |  |
| pPI159       | Ampicilin                        |  |  |
| pPI437       | Ampicilin                        |  |  |
| pPI54        | Ampicilin                        |  |  |
| pDM1209      | Ampicilin                        |  |  |
| pDM1210      | Ampicilin                        |  |  |
| pPI143       | Ampicilin                        |  |  |
| pPI459       | Ampicilin                        |  |  |
| pPI142       | Ampicilin                        |  |  |
|              | shu                              |  |  |
| pDM344       | Ampicilin                        |  |  |
| pDM1019      | Ampicilin                        |  |  |
| pDM1018      | Ampicilin                        |  |  |
| pPI152       | Ampicilin                        |  |  |
| pPI418       | Ampicilin                        |  |  |
| pPI150       | Ampicilin                        |  |  |
| pDM1021      | Ampicilin                        |  |  |
| pDM1020      | Ampicilin                        |  |  |
| pPI153       | Ampicilin                        |  |  |
| pPI457       | Ampicilin                        |  |  |
| pPI151       | Ampicilin                        |  |  |
|              | inducible extrachror             |  |  |
| pDM1038      | Ampicilin                        |  |  |
| pDM1047      | Ampicilin                        |  |  |
| pDM1046      | Ampicilin                        |  |  |
| pPI450       | Ampicilin                        |  |  |
| pPI452       | Ampicilin                        |  |  |
| pPI449       | Ampicilin                        |  |  |
| pDM1049      | Ampicilin                        |  |  |
| pDM1048      | Ampicilin                        |  |  |
| pPI470       | Ampicilin                        |  |  |
| pPI460       | Ampicilin                        |  |  |
| pPI469       | Ampicilin                        |  |  |
|              | act5 safe hav                    |  |  |
| pDM1501      | Ampicilin                        |  |  |
| pDM1513      | Ampicilin                        |  |  |
| pDM1514      | Ampicilin                        |  |  |
| pPI231       | Ampicilin                        |  |  |
| pPI419       | Ampicilin                        |  |  |
| pPI228       | Ampicilin                        |  |  |

| pDM1515         Ampicilin           pDM1516         Ampicilin           pPI230         Ampicilin           pPI458         Ampicilin           pPI458         Ampicilin           pPI229         Ampicilin           REMI ex           pDM1220         Ampicilin           pDM1351         Ampicilin           pDM1351         Ampicilin           pDM1259         Ampicilin           pPI465         Ampicilin           pPI468         Ampicilin           pPI468         Ampicilin           pDM1352         Ampicilin           pDM1305         Ampicilin           pPI471         Ampicilin           pPI467         Ampicilin           pPI472         Ampicilin           pPI461         Ampicilin           pPI462         Ampicilin           pPI463         Ampicilin           pPI463         Ampicilin           pDM1079         Ampicilin           pDM1080         Ampicilin           pDM1081         Ampicilin  |         |           |  |  |
|--|---------|-----------|--|--|
| pPI230 Ampicilin pPI458 Ampicilin  pPI229 Ampicilin  REMI ex  pDM1220 Ampicilin  pDM1351 Ampicilin  pPM1259 Ampicilin  pPI465 Ampicilin  pPI466 Ampicilin  pDM1352 Ampicilin  pDM1305 Ampicilin  pPI471 Ampicilin  pPI471 Ampicilin  pPI472 Ampicilin  pPI462 Ampicilin  pPI463 Ampicilin  pPI463 Ampicilin  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin  pM1080 Ampicilin  pPI471 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin   | pDM1515 | Ampicilin |  |  |
| pPI458 Ampicilin  pPI229 Ampicilin  REMI ex  pDM1220 Ampicilin  pDM1351 Ampicilin  pDM1259 Ampicilin  pPI465 Ampicilin  pPI466 Ampicilin  pDM1352 Ampicilin  pDM1305 Ampicilin  pPI471 Ampicilin  pPI472 Ampicilin  pPI472 Ampicilin  pPI472 Ampicilin  pPI461 Ampicilin  pPI462 Ampicilin  pPI463 Ampicilin  pPI463 Ampicilin  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin  REMI ex  Ampicilin  Ampicilin  pPI465 Ampicilin  knoci   | pDM1516 | Ampicilin |  |  |
| pPI229 Ampicilin  REMI ex  pDM1220 Ampicilin  pDM1351 Ampicilin  pDM1259 Ampicilin  pPI465 Ampicilin  pPI468 Ampicilin  pPI466 Ampicilin  pDM1352 Ampicilin  pDM1305 Ampicilin  pPI471 Ampicilin  pPI472 Ampicilin  pPI472 Ampicilin  pPI472 Ampicilin  pPI464 Ampicilin  pPI464 Ampicilin  pPI463 Ampicilin  pDM1080 Ampicilin  pDM1080 Ampicilin  Ampicilin  REMI ex  Ampicilin  pPI465 Ampicilin  Ampicilin  knoci  | pPI230  | Ampicilin |  |  |
| PDM1220 Ampicilin  pDM1351 Ampicilin  pDM1259 Ampicilin  pPI465 Ampicilin  pPI468 Ampicilin  pDM1352 Ampicilin  pDM1305 Ampicilin  pPI471 Ampicilin  pPI467 Ampicilin  pPI472 Ampicilin  pPI472 Ampicilin  pPI461 Ampicilin  pPI462 Ampicilin  pPI463 Ampicilin  pPI463 Ampicilin  pDM1080 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin  Ampicilin  Ampicilin  knocl  | pPI458  | Ampicilin |  |  |
| pDM1220 Ampicilin pDM1351 Ampicilin pDM1259 Ampicilin pPI465 Ampicilin pPI468 Ampicilin pPI466 Ampicilin pDM1352 Ampicilin pDM1305 Ampicilin pPI471 Ampicilin pPI472 Ampicilin pPI472 Ampicilin pPI472 Ampicilin pPI461 Ampicilin pPI462 Ampicilin pPI463 Ampicilin pPI463 Ampicilin pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin   | pPI229  | Ampicilin |  |  |
| pDM1351 Ampicilin pDM1259 Ampicilin pPI465 Ampicilin pPI468 Ampicilin pPI466 Ampicilin pDM1352 Ampicilin pDM1305 Ampicilin pPI471 Ampicilin pPI472 Ampicilin pPI472 Ampicilin pPI472 Ampicilin pPI461 Ampicilin pPI462 Ampicilin pPI463 Ampicilin pPI463 Ampicilin pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin   |         | REMI ex   |  |  |
| pDM1259     pPl465     Ampicilin     pPl468     Ampicilin     pPl466     Ampicilin     pDM1352     Ampicilin     pDM1305     Ampicilin     pPl471     Ampicilin     pPl467     Ampicilin     pPl472     Ampicilin     targeted     pDM1355     Ampicilin     pPl461     Ampicilin     pPl462     Ampicilin     pPl463     Ampicilin     pPl463     Ampicilin     pDM1079     Ampicilin     pDM1080     Ampicilin     Ampicilin     Ampicilin     Ampicilin     Ampicilin   | pDM1220 | Ampicilin |  |  |
| pPI465 Ampicilin pPI468 Ampicilin pPI466 Ampicilin pDM1352 Ampicilin pDM1305 Ampicilin pPI471 Ampicilin pPI467 Ampicilin pPI472 Ampicilin  pPI472 Ampicilin  pPI461 Ampicilin pPI462 Ampicilin pPI463 Ampicilin pPI463 Ampicilin pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin Ampicilin Ampicilin   | pDM1351 | Ampicilin |  |  |
| pPI468 Ampicilin pPI466 Ampicilin pDM1352 Ampicilin pDM1305 Ampicilin pPI471 Ampicilin pPI467 Ampicilin pPI472 Ampicilin  pDM1355 Ampicilin  pPI461 Ampicilin pPI462 Ampicilin pPI464 Ampicilin pPI463 Ampicilin  pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin Ampicilin  | pDM1259 | Ampicilin |  |  |
| pPI466 Ampicilin pDM1352 Ampicilin pDM1305 Ampicilin pPI471 Ampicilin pPI467 Ampicilin pPI472 Ampicilin  pPI472 Ampicilin  pDM1355 Ampicilin pPI461 Ampicilin pPI462 Ampicilin pPI464 Ampicilin pPI463 Ampicilin pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin Ampicilin Ampicilin   | pPI465  | Ampicilin |  |  |
| pDM1352 Ampicilin pDM1305 Ampicilin pPI471 Ampicilin pPI467 Ampicilin  pPI472 Ampicilin  targeted pDM1355 Ampicilin pPI461 Ampicilin pPI462 Ampicilin pPI464 Ampicilin pPI463 Ampicilin  pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin Ampicilin Ampicilin   | pPI468  | Ampicilin |  |  |
| pDM1305 Ampicilin  pPI471 Ampicilin  pPI467 Ampicilin  pPI472 Ampicilin  targeted  pDM1355 Ampicilin  pPI461 Ampicilin  pPI462 Ampicilin  pPI464 Ampicilin  pPI463 Ampicilin  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin  Ampicilin  Ampicilin  Ampicilin  Ampicilin  Ampicilin  Ampicilin  Ampicilin   | pPI466  | Ampicilin |  |  |
| pPI471         Ampicilin           pPI467         Ampicilin           pPI472         Ampicilin           targeted           pDM1355         Ampicilin           pPI461         Ampicilin           pPI462         Ampicilin           pPI463         Ampicilin           pDM1079         Ampicilin           pDM1080         Ampicilin           pDM1081         Ampicilin   | pDM1352 | Ampicilin |  |  |
| pPI467 Ampicilin pPI472 Ampicilin  targeted  pDM1355 Ampicilin  pPI461 Ampicilin  pPI462 Ampicilin  pPI464 Ampicilin  pPI463 Ampicilin  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin  Ampicilin  Ampicilin  | pDM1305 | Ampicilin |  |  |
| pPI472 Ampicilin  targeted  pDM1355 Ampicilin  pPI461 Ampicilin  pPI462 Ampicilin  pPI464 Ampicilin  pPI463 Ampicilin  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin   | pPI471  | Ampicilin |  |  |
| pDM1355 Ampicilin pPI461 Ampicilin pPI462 Ampicilin pPI464 Ampicilin pPI463 Ampicilin  pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin   | pPI467  | ·         |  |  |
| pDM1355 Ampicilin pPI461 Ampicilin pPI462 Ampicilin pPI464 Ampicilin pPI463 Ampicilin  pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin   | pPI472  | Ampicilin |  |  |
| pPI461 Ampicilin  pPI462 Ampicilin  pPI464 Ampicilin  pPI463 Ampicilin  knocl  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin   |         | targeted  |  |  |
| pPI462 Ampicilin pPI464 Ampicilin pPI463 Ampicilin  math description by the point of the point o | pDM1355 | Ampicilin |  |  |
| pPI464 Ampicilin pPI463 Ampicilin  knocl pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin   | pPI461  | Ampicilin |  |  |
| pPI463 Ampicilin  knocl  pDM1079 Ampicilin  pDM1080 Ampicilin  pDM1081 Ampicilin   | pPI462  | Ampicilin |  |  |
| pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin  | pPI464  | Ampicilin |  |  |
| pDM1079 Ampicilin pDM1080 Ampicilin pDM1081 Ampicilin  | pPI463  | Ampicilin |  |  |
| pDM1080 Ampicilin pDM1081 Ampicilin  |         | knocl     |  |  |
| pDM1081 Ampicilin  | pDM1079 | Ampicilin |  |  |
| ·  | pDM1080 | Ampicilin |  |  |
|  | pDM1081 | Ampicilin |  |  |
| pDM1082 Ampicilin  | pDM1082 | Ampicilin |  |  |
| CRE exp  |         | CRE exp   |  |  |
| pDM1483 Ampicilin  | pDM1483 | Ampicilin |  |  |
| pDM1489 Ampicilin  | pDM1489 | Ampicilin |  |  |
| pDM1488 Ampicilin  | pDM1488 | Ampicilin |  |  |

| resistance/selection in Dictyostelium | tag                                     |  |  |
|---------------------------------------|---|--|--|
| mal expression plasmids               |   |  |  |
| G418                                  | no                                      |  |  |
| G418                                  | N-terminal GFP                          |  |  |
| G418                                  | N-terminal mCherry                      |  |  |
| G418                                  | N-terminal mNeon                        |  |  |
| G418                                  | N-terminal mScarlet                     |  |  |
| G418                                  | N-terminal mTurquoise2                  |  |  |
| G418                                  | C-terminal GFP                          |  |  |
| G418                                  | C-terminal mCherry                      |  |  |
| G418                                  | C-terminal mNeon                        |  |  |
| G418                                  | C-terminal mScarlet                     |  |  |
| G418                                  | C-terminal mTurquoise2                  |  |  |
| ttle plasmids                         | 1 |  |  |
| no                                    | no                                      |  |  |
| no                                    | N-terminal GFP                          |  |  |
| no                                    | N-terminal mCherry                      |  |  |
| no                                    | N-terminal mNeon                        |  |  |
| no                                    | N-terminal mScarlet                     |  |  |
| no                                    | N-terminal mTurquoise2                  |  |  |
| no                                    | C-terminal GFP                          |  |  |
| no                                    | C-terminal mCherry                      |  |  |
| no                                    | C-terminal mNeon                        |  |  |
| no                                    | C-terminal mScarlet                     |  |  |
| no                                    | C-terminal mTurquoise2                  |  |  |
| nosomal expression plasmids           |   |  |  |
| <br>Hygromycin                        | no                                      |  |  |
| Hygromycin                            | N-terminal GFP                          |  |  |
| Hygromycin                            | N-terminal mCherry                      |  |  |
| Hygromycin                            | N-terminal mNeon                        |  |  |
| Hygromycin                            | N-terminal mScarlet                     |  |  |
| Hygromycin                            | N-terminal mTurquoise2                  |  |  |
| Hygromycin                            | C-terminal GFP                          |  |  |
| Hygromycin                            | C-terminal mCherry                      |  |  |
| Hygromycin                            | C-terminal mNeon                        |  |  |
| Hygromycin                            | C-terminal mScarlet                     |  |  |
| Hygromycin                            | C-terminal mTurquoise2                  |  |  |
| en targeting plasmids                 |   |  |  |
| Hygromycin                            | no                                      |  |  |
| Hygromycin                            | N-terminal GFP                          |  |  |
| Hygromycin                            | N-terminal mCherry                      |  |  |
| Hygromycin                            | N-terminal mNeon                        |  |  |
| Hygromycin                            | N-terminal mScarlet                     |  |  |
| Hygromycin                            | N-terminal mTurquoise2                  |  |  |
| 10 - 1-11                             |   |  |  |

| Hygromycin                            | C-terminal GFP         |  |  |
|---------------------------------------|------------------------|--|--|
| Hygromycin                            | C-terminal mCherry     |  |  |
| Hygromycin                            | C-terminal mNeon       |  |  |
| Hygromycin                            | C-terminal mScarlet    |  |  |
| Hygromycin                            | C-terminal mTurquoise2 |  |  |
| pression plasmids                     |                        |  |  |
| Hygromycin                            | no                     |  |  |
| Hygromycin                            | N-terminal GFP         |  |  |
| Hygromycin                            | N-terminal mCherry     |  |  |
| Hygromycin                            | N-terminal mNeon       |  |  |
| Hygromycin                            | N-terminal mScarlet    |  |  |
| Hygromycin                            | N-terminal mTurquoise2 |  |  |
| Hygromycin                            | C-terminal GFP         |  |  |
| Hygromycin                            | C-terminal mCherry     |  |  |
| Hygromycin                            | C-terminal mNeon       |  |  |
| Hygromycin                            | C-terminal mScarlet    |  |  |
| Hygromycin                            | C-terminal mTurquoise2 |  |  |
| in frame plasmids                     |                        |  |  |
| Hygromycin                            | C-terminal GFP         |  |  |
| Hygromycin                            | C-terminal mCherry     |  |  |
| Hygromycin                            | C-terminal mNeon       |  |  |
| Hygromycin                            | C-terminal mScarlet    |  |  |
| Hygromycin                            | C-terminal mTurquoise2 |  |  |
| k-out plasmids                        |                        |  |  |
| Blasticidin                           | no                     |  |  |
| Nourseothricin                        | no                     |  |  |
| Hygromycin                            | no                     |  |  |
| G418                                  | no                     |  |  |
| ression plasmids                      |                        |  |  |
| Nourseothricin                        | no                     |  |  |
| Hygromycin                            | no                     |  |  |
| G418                                  | no                     |  |  |
| · · · · · · · · · · · · · · · · · · · |                        |  |  |

| PCR program  | n     |
|--|-------|
| step   |       |
| Initial Denaturation   |       |
| 30 Cycles  |       |
|  |       |
|  |       |
| Final Extension  |       |
| Hold   |       |
| Reaction compo   | sitio |
| component  |       |
| 10 μM Forward Primer   |       |
| 10 μM Reverse Primer   |       |
| Template DNA   |       |
| 2X Master Mix with Standard Buffer including polymerase (see table of materials) |       |
| Nuclease-free water  |       |

| temperature         | time                |
|---------------------|---------------------|
| 94 °C               | 30 seconds          |
| 94 °C               | 15-30 seconds       |
| 42 °C               | 15-60 seconds       |
| 68 °C               | 1 minute/kb         |
| 68 °C               | 5 minutes           |
| 4-10 °C             |                     |
| 1                   |                     |
| 25 μl reaction      | final concentration |
| 0.5 μL              | 0.2 μΜ              |
| 0.5 μL              | 0.2 μΜ              |
| variable (ca. 5 μL) | < 1,000 ng          |
| 12.5 μL             | 1X                  |
| to 25 μL            | < 1,000 ng          |

| targeted construct into the act5 locus | plasmid name | number of occupied wells |
|--|--------------|--------------------------|
| LifeAct-mCherry                        | pPI226       | 7                        |
| LifeAct-GFP                            | pPI227       | 12                       |
| GFP                                    | pDM1513      | 3                        |
| mCherry                                | pDM1514      | 3                        |
| GFP                                    | pDM1513      | 66                       |
| mCherry                                | pDM1514      | 221                      |
| H2B-mCherry                            | pPI420       | 3                        |
| H2B-mCherry                            | pPI420       | 7                        |
| mCherry                                | pDM1514      | 10                       |
| mCherry                                | pDM1514      | 240                      |
| mCherry                                | pDM1514      | 320                      |

| number of checked clones | Positive clones | Correct clones (%) | Dictyostelium strain used |
|--------------------------|-----------------|--------------------|---------------------------|
| 7                        | 1               | 14.2               | AX2                       |
| 12                       | 5               | 41.6               | AX2                       |
| 3                        | 2               | 66.6               | AX2                       |
| 3                        | 1               | 33.3               | AX2                       |
| 9                        | 5               | 55.5               | AX2                       |
| 12                       | 10              | 83.3               | AX2                       |
| 3                        | 1               | 33.3               | AX2                       |
| 7                        | 6               | 85.7               | AX2                       |
| 10                       | 7               | 70                 | DdB                       |
| 12                       | 11              | 91.6               | DdB                       |
| 12                       | 12              | 100                | NC4                       |

| transfection efficiency (transfectants/2x10^6/1 μg DNA) |
|---|
| 3.5x10^-6   |
| 6x10^-6   |
| 1.5x10^-6   |
| 1.5x10^-6   |
| 3.3x10^-5   |
| 1.1x10^-4   |
| 1.5x10^-6   |
| 3.5x10^-6   |
| 5x10^-6   |
| 1.2x10^-4   |
| 1.6x10^-4   |

| Name of Material/ Equipment                           | Company              | Catalog Number | Comments/Description |
|---|----------------------|----------------|----------------------|
| Equipment   |                      |                |                      |
| Eppendorf Microcentrifuges 5424/5424R                 | ThermoScientific     | 05-400-002     |                      |
|   |                      |                |                      |
| Eppendorf 5702R Centrifuges with A-4-38 Model Rotor   | ThermoScientific     | 12823252       |                      |
| Eppendorf Mastercycler Nexus Thermal Cyclers          | Sigma Aldrich        | EP6331000025   |                      |
| Gene Pulser X Cell, including CE & PC modules         | BioRad               | 1652660        |                      |
| Safety Cabinet Foruna - SCANLAF                       | Labogene             |                |                      |
| BioPhotometer Plus                                    | Eppendorf            |                |                      |
| CLSM 710  | Zeiss                |                |                      |
| Media & Agaroses                                      |                      |                |                      |
| LoFlo Medium  | Formedium            | LF0501         |                      |
| Seakem GTG Agarose                                    | Lonza                | 50071          |                      |
| Low EEO Agarose                                       | BioGene              | 300-200        |                      |
| Purified Agar   | Oxoid                | LP0028         |                      |
| SM broth  | Formedium            | SMB0102        |                      |
| 2x LB broth   | Formedium            | LBD0102        |                      |
| Chemicals   |                      |                |                      |
| SYBR Safe DNA Gel Stain                               | ThermoScientific     | S33102         |                      |
| 1 Kb Plus DNA Ladder                                  | ThermoScientific     | 10787018       |                      |
| 1 Kb DNA Ladder                                       | NEB                  | N3232L         |                      |
| HEPES free acid                                       | Sigma Aldrich/Merck  | 391340 EMD     |                      |
| KH <sub>2</sub> PO <sub>4</sub>                       | VWR                  | P/4800/53      |                      |
| Na <sub>2</sub> HPO <sub>4</sub> * 2 H <sub>2</sub> O | VWR                  | 10028-24-7     |                      |
| MgCl <sub>2 *</sub> 6 H <sub>2</sub> O                | Sigma Aldrich/Merck  | 5982 EMD       |                      |
| CaCl <sub>2</sub> * 2 H <sub>2</sub> O                | Sigma Aldrich        | 442909         |                      |
| Folic Acid  | Sigma Aldrich        | F7876          |                      |
| КОН   | VWR                  | 26668.263      |                      |
| Cultur Dishes   |                      |                |                      |
| 96 Well Cell Culture Cluster, Flat Bottom with Low    |                      |                |                      |
| Evaporation Lid, Tissue Culture Treated               | Corning Incorporated | 3595           |                      |

| 6 Well Cell Culture Cluster, Flat Bottom with Lid, Tissue |                            |               |  |
|---|----------------------------|---------------|--|
| Culture Treated   | Corning Incorporated       | 3516          |  |
| 100 x 20 mm style Tissue Culture Dish, Tissue Culture     | 5 .                        |               |  |
| Treated   | Corning Incorporated       | 353003        |  |
| 50 mm Glass Bottom Microwell Dishes No1.5                 | MatTek Corporation         | P50G-1.5-30-F |  |
| Antibiotics   |                            |               |  |
|   |                            |               |  |
| Geneticin G418-sulphate                                   | Gibco by Life Technologies | 11811-023     |  |
| Hygromycin B Gold   | InvivoGen                  | ant-hg-1      |  |
| Additional Consumables                                    |                            |               |  |
| 2mm gap electroporation cuvettes, long electrode          | Geneflow Limited           | E6-0062       |  |
| 10 μl Inoculating Loop, Blue 10 Micro L                   | ThermoScientific           | 129399        |  |
| Spreader, L-shaped, sterile                               | greiner bio-one            | 730190        |  |
| Combitips advanced 5 ml                                   | Eppendorf BIOPUR           | 30089669      |  |
| Kits  |                            |               |  |
| ZR Plasmid Miniprep Classic                               | Zymoresearch               | D4016         |  |
| Quick DNA Miniprep Kit                                    | Zymoresearch               | D3025         |  |
| Zymoclean DNA Recovery Kit                                | Zymoresearch               | D40002        |  |
| Enzymes   |                            |               |  |
| Restriction enzymes                                       | NEB                        |               |  |
| OneTaq 2X Master Mix with Standard Buffer                 | NEB                        | M0482L        |  |
| T4 DNA Ligase   | NEB                        | M0202S        |  |
| PrimeSTAR Max DNA Polymerase                              | TakaraBio                  | R045A         |  |



## ARTICLE AND VIDEO LICENSE AGREEMENT - UK

| Title of Article: Genetic engineering of atonic and non-atonic  |
|---|
| Author(s): Selection and growth on backeria   |
| Item 1 (check one box): The Author elects to have the Materials be made available (as described at  |
| http://www.jove.com/author) via: Standard Access Open Access  |
| Item 2 (check one box):   |
| Item 2 (check one box):  The Author is NOT a United States government employee.  The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.  The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.  The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.  The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.  The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.  The Author is a United States government employee. |

## **ARTICLE AND VIDEO LICENSE AGREEMENT**

Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution 3.0 Agreement (also known as CC-BY), the terms conditions of which can be found http://creativecommons.org/licenses/by/3.0/us/legalcode; "Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a musical arrangement, dramatization,

1. Defined Terms. As used in this Article and Video License

upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments;

"Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

- 2. <u>Background</u>. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.
- 3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and
- (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.
- 4. <u>Retention of Rights in Article.</u> Notwithstanding the exclusive license granted to JoVE in Section 3 above, the



## ARTICLE AND VIDEO LICENSE AGREEMENT - UK

Author shall, with respect to the Article, retain the nonexclusive right to use all or part of the Article for the noncommercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the

Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims

all such rights and transfers all such rights to JoVE.

- 6. Grant of Rights in Video Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats.
- 7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict

- 8. <u>Likeness, Privacy, Personality</u>. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.
- 9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.
- 10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including,



## ARTICLE AND VIDEO LICENSE AGREEMENT - UK

without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JOVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or

damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

- 12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.
- 13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

| AUTHOR:        |  |     |
|----------------|--|-----|
| Name:          | Peggy Paschee  |     |
| Department:    | Division of Cell Biology   | 110 |
| Institution:   | MRC Laborator of Molecular Biology Cambridge   | ik  |
| Article Title: | genetic engineering of axmic and mon-axenic wild-ty Dictyostelium discoideum alls based on the Selection and growth on | pe  |
|                | Dictyostelium discoideum alls based on the   |     |
|                | Pastelle 22-08 - 2018 5acto  | nia |
| Signature:     | Date:  |     |
|                |  |     |

Please submit a signed and dated copy of this license by one of the following three methods:

- Upload a scanned copy as a PDF to the JoVE submission site upon manuscript submission (preferred);
- 2) Fax the document to +1.866.381.2236; or
- 3) Mail the document to JoVE / Atn: JoVE Editorial / 1 Alewife Center Suite 200 / Cambridge, MA 02140

For questions, please email editorial@jove.com or call +1.617.945.9051.

| MS # (internal use): |  |
|----------------------|--|

Dear Vineeta Bajaj,

Many thanks for considering our manuscript "Genetic Engineering of *Dictyostelium discoideum* Cells Based on the Selection and Growth on Bacteria " for publication. Your comments were very informed. We now submit a revised version of the manuscript with changes made in response to your comments.

Yours sincerely, Peggy Paschke

1. The editor has formatted the manuscript to match the journal's format. Please retain the same.

We have retained the same file and changed the protocol regarding the suggestions made by the editor.

2. Please address all the specific comments marked in the manuscript.

We have addressed the points made within the manuscript and added citation where requested and changed the style of the protocol to match the JOVE requirements. We have slightly changed the structure of our discussion to make our points more clear.

In general we feel, that we address all questions required for a method journal. The limitations of our protocol is clearly the need to re-create already existing plasmids, due to the special requirements of promoter sequences needed for expression in bacterial grown *D. discoideum* cells as stated in the discussion. Especially the fact that commonly used selectable marker blasticidin does not work in our conditions is a huge disadvantage and can just be overcome with the recreation of new knock- out plasmids, as we have mentioned as well. The main future perspective it to combine the CRISPR/Cas9 technology with our transfection protocols. It would solve the problems arising from the lack of workability of Blasticidin and the need the recreate knock-out constructs. Additionally the perspective to quickly knock-out genes in fresh wild-type isolates is very tempting. As mentioned in another paragraph the possibility to rule out syntetic phenotypes which are result of different axenic backgrounds is another perspective for future directions. Mentioned should be also the possiblity to investigate uncorrupted moltility/chemotaxis since high levels of macropinocytosis are not a requirement anymore for cell transfection and maintenance.

Due to great simplicty of our protocol the only critical step is the electoporation.

3. For the protocol section, please remove redundancy make the steps as crisp as you can providing all specific details with respect to your experiment.

Redundant steps have been removed.

4. We cannot have a non-numbered step or paragraph in the protocol section. Every step should bnumbered. e.g., 1 should be followed by 1.1 and then 1.1.1 and 1.1.2 if necessary.

That should realised now by now.

6. The Protocol should contain only action items that direct the reader to do something. Also, every step should be in imperative tense as if directing someone how to perform your experiment.

All steps lacking imperative have been removed are have transformed into direct commands.

7. Once formatted please ensure that the highlight is no more than 2.75 pages in length including heading and spacing and the total protocol length do not exceed 10 pages.

We have checked the length of highlighted protocol. It should including spaces excatly math the requirement of 2.75 pages.

8. Please reword lines 98-101 as it matches with the previously published literature. In compliance with data protection regulations, please contact the publication office if you would like to have your personal information removed from the database.

The passage has been reworded. W have stated as well if parts of a prepublished figure or table were used. That is confirm with the PLOS One policies (https://www.plos.org/license).

| Cell line              | Genetically background | Reference number |
|------------------------|------------------------|------------------|
| AX2 (Ka)               |                        | DBS0235521       |
| NC4 (S)                |                        |                  |
| act5 ::mCherry Clone 5 | NC4                    | HM1912           |
| act5::GFP Clone 2      | AX2                    | HM1930           |
| V12M2                  |                        |                  |
| WS2162                 |                        |                  |

| Published before               | Туре          |
|--------------------------------|---------------|
| Bloomfield <i>et al</i> , 2008 | wild type     |
| Bloomfield <i>et al</i> , 2008 | wild type     |
| Paschke <i>et al</i> , 2018    | act5 knock-in |
| Paschke <i>et al</i> , 2018    | act5 knock-in |
| Bloomfield <i>et al</i> , 2008 | wild type     |
| Bloomfield <i>et al</i> , 2008 | wild type     |